Lumos Diagnostics Holdings Limited
ASX: LDX.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Douglas Ward
- Headquarters
- Melbourne, Australia
- IPO year
- 2021
- Market cap
- A$114.5M
- Website
- https://lumosdiagnostics.com
Loading LDX…
Loading profile data…Frequently asked questions about LDX
What does Lumos Diagnostics Holdings Limited (LDX.AX) do?
Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting an...
Where does LDX.AX trade?
Lumos Diagnostics Holdings Limited (LDX.AX) trades on the Australian Securities Exchange.
What sector is LDX.AX in?
Lumos Diagnostics Holdings Limited (LDX.AX) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Lumos Diagnostics Holdings Limited?
Douglas Ward is the chief executive officer of Lumos Diagnostics Holdings Limited (LDX.AX).
Where is Lumos Diagnostics Holdings Limited headquartered?
Lumos Diagnostics Holdings Limited is headquartered in Australia.
Does LDX.AX pay a dividend?
Lumos Diagnostics Holdings Limited (LDX.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LDX.AX go public?
Lumos Diagnostics Holdings Limited (LDX.AX) completed its initial public offering in 2021.